Kidney Biomarkers and Major Adverse Kidney Events in Critically Ill Patients

Flannery, Alexander H.; Bosler, Katherine; Ortiz-Soriano, Victor; Gianella, Fabiola; Prado, Víctor; Lambert, Joshua; Toto, Robert D.; Moe, Orson W.; Neyra, Javier A.

doi:10.34067/kid.0003552020

Cited by 10 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, FBG plays a crucial role in the regulation and activation of coagulation proteins during platelet aggregation. This process is largely supported by fibrin’s products, Fibrinopeptide A and B proteins, and activated factor XIII (FXIII), which are forming solid clot network [ 56 , 57 ]. However, fibrinogen has been associated with some serious medical condition, not only systematic inflammation but also with AKI [ 58 ].…”

Section: Resultsmentioning

confidence: 99%

Recent Advances of Proteomics in Management of Acute Kidney Injury

Pejchinovski¹,

Türkkan²,

Pejchinovski

2023

Diagnostics

View full text Add to dashboard Cite

Acute Kidney Injury (AKI) is currently recognized as a life-threatening disease, leading to an exponential increase in morbidity and mortality worldwide. At present, AKI is characterized by a significant increase in serum creatinine (SCr) levels, typically followed by a sudden drop in glomerulus filtration rate (GFR). Changes in urine output are usually associated with the renal inability to excrete urea and other nitrogenous waste products, causing extracellular volume and electrolyte imbalances. Several molecular mechanisms were proposed to be affiliated with AKI development and progression, ultimately involving renal epithelium tubular cell-cycle arrest, inflammation, mitochondrial dysfunction, the inability to recover and regenerate proximal tubules, and impaired endothelial function. Diagnosis and prognosis using state-of-the-art clinical markers are often late and provide poor outcomes at disease onset. Inappropriate clinical assessment is a strong disease contributor, actively driving progression towards end stage renal disease (ESRD). Proteins, as the main functional and structural unit of the cell, provide the opportunity to monitor the disease on a molecular level. Changes in the proteomic profiles are pivotal for the expression of molecular pathways and disease pathogenesis. Introduction of highly-sensitive and innovative technology enabled the discovery of novel biomarkers for improved risk stratification, better and more cost-effective medical care for the ill patients and advanced personalized medicine. In line with those strategies, this review provides and discusses the latest findings of proteomic-based biomarkers and their prospective clinical application for AKI management.

show abstract

Section: Resultsmentioning

confidence: 99%

Recent Advances of Proteomics in Management of Acute Kidney Injury

Pejchinovski¹,

Türkkan²,

Pejchinovski

2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Table 2 describes the observation periods for MAKE evaluation. Most articles (104 articles) evaluated MAKE at a single moment in time, while 18 articles [22,27,43,46,48,92,94,97,103,108,109,112,117,129,133,135,138,140] evaluated MAKE at multiple time points. Overall, thirteen different observation periods were employed across articles, with 30 days (27.9% in single period articles, 55.6% in multiple period articles) and 90 days (22.1% in single period articles, 77.8% in multiple period articles) as the most frequently used periods for evaluation.…”

Section: Observation Period For Make Evaluationmentioning

confidence: 99%

Heterogeneity in the definition of major adverse kidney events: a scoping review

Maeda,

Inokuchi,

Bellomo

et al. 2024

Intensive Care Med

View full text Add to dashboard Cite

Acute kidney injury (AKI) is associated with persistent renal dysfunction, the receipt of dialysis, dialysis dependence, and mortality. Accordingly, the concept of major adverse kidney events (MAKE) has been adopted as an endpoint for assessing the impact of AKI. However, applied criteria or observation periods for operationalizing MAKE appear to vary across studies. To evaluate this heterogeneity for MAKE evaluation, we performed a systematic scoping review of studies that employed MAKE as an AKI endpoint. Four major academic databases were searched, and we identified 122 studies with increasing numbers over time. We found marked heterogeneity in applied criteria and observation periods for MAKE across these studies, with some even lacking a description of criteria. Moreover, 13 different observation periods were employed, with 30 days and 90 days as the most common. Persistent renal dysfunction was evaluated by estimated glomerular filtration rate (34%) or serum creatinine concentration (48%); however, 37 different definitions for this component were employed in terms of parameters, cut-off criteria, and assessment periods. The definition for the dialysis component also showed significant heterogeneity regarding assessment periods and duration of dialysis requirement (chronic vs temporary). Finally, MAKE rates could vary by 7% [interquartile range: 1.7-16.7%] with different observation periods or by 36.4% with different dialysis component definitions. Our findings revealed marked heterogeneity in MAKE definitions, particularly regarding component assessment and observation periods. Dedicated discussion is needed to establish uniform and acceptable standards to operationalize MAKE in terms of selection and applied criteria of components, observation period, and reporting criteria for future trials on AKI and related conditions.

show abstract

“…The kindred composite outcome of MAKE has made a rather slow debut in the nephrology literature. 6,7 One advantage of including declining GFR in a composite outcome is that it addresses the increasing rates of patients with cirrhosis and underlying CKD. Nevertheless, there are caveats to using composite outcomes.…”

Section: N V I T E D E D I T O R I a Lmentioning

confidence: 99%

“…The composite outcome of MACE, major adverse cardiovascular events, came about to reduce the sample size needed and shorten duration of clinical trials. The kindred composite outcome of MAKE has made a rather slow debut in the nephrology literature 6,7 . One advantage of including declining GFR in a composite outcome is that it addresses the increasing rates of patients with cirrhosis and underlying CKD.…”

mentioning

confidence: 99%